Developer docs
API playgroundTry for free, no card

Search company profiles

BioMedomics

Full company profile

uuid000csa5

Namestring
BioMedomics
Legal namestring
BioMedomics, Inc.
Websiteurl
biomedomics.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

BioMedomics is a privately-held point-of-care diagnostics company headquartered in Morrisville, North Carolina, founded in 2006-2007. The company develops lateral flow immunoassay (LFIA)-based rapid diagnostic tests for clinical and field settings without centralized laboratory infrastructure, with a primary focus on sickle cell disease (SCD) screening in resource-limited regions of Sub-Saharan Africa, the Middle East, and South Asia. Its operations are housed in a 15,000-square-foot ISO 13485-compliant research and manufacturing facility in the Research Triangle Park area.

The company's product portfolio is anchored by Sickle SCAN and Sickle SCAN-EZ — multiplexed, qualitative point-of-care immunoassays that simultaneously detect hemoglobins A, S, and C, enabling clinicians to distinguish normal, carrier, and sickle cell disease samples in 5 minutes with combined sensitivity and specificity exceeding 99% (validated against hemoglobin electrophoresis). Sickle SCAN uses a 5 µL fingerstick blood sample in cassette format, while Sickle SCAN-EZ is a 2 µL strip format designed for high-volume public-health screening at a lower per-test price. Adjacent products include Fungi SCAN (an all-in-one fluorescent KOH fungal staining reagent), Femi SCAN (a dual fluorescence staining agent for vaginal infections), and previously SARS-CoV-2 antigen and COVID-19 IgM-IgG antibody rapid tests. The company claims to be the world's leading manufacturer of hemoglobin subtype antibodies (A, C, E, F, S), supporting an intellectual property portfolio of 15 granted patents with 13 additional applications pending, backed by over $25 million in cumulative R&D investment.

BioMedomics operates a capital-light, channel-driven commercial model, selling through authorized distribution partners in more than 40 countries including Helena Laboratories (Australia), Laborex Tanzania (Tanzania), and Assene-Laborex (Nigeria). Pricing is quote-based with no publicly disclosed list rates; prospective buyers are routed through a Request Quote form and direct sales contact. The company supplements partner-channel sales with grant-funded screening initiatives — most notably a 3-year Sickle Cell Disease Independent Research Grant program in Sub-Saharan Africa launched in June 2024 — and with event-driven awareness campaigns in partnership with healthcare providers, NGOs, and patient brand ambassadors. The company is ISO 13485:2016 certified by BSI Group of America and holds regional approvals including CE mark, Saudi FDA, Australian TGA, and Tanzania TMDA. None of BioMedomics' products are currently approved for in vitro diagnostic use in the United States. In November 2025, BioMedomics was acquired by OraSure Technologies (NASDAQ: OSUR) for approximately $4 million, becoming a wholly-owned subsidiary focused on expanding sickle cell disease testing into Africa and Latin America.

Short descriptiontext

BioMedomics, a Morrisville, NC-based point-of-care diagnostics company, develops lateral flow immunoassay tests for sickle cell disease, fungal infections, and women's health, distributed through partners in 40+ countries. Acquired by OraSure Technologies in November 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMorrisville, United States
HQ citystring
Morrisville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, lateral flow immunoassay, sickle cell testing, rapid diagnostic tests, in-vitro diagnostics
Industry1 code
SECONDARYHLAAALAH
Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In-Vitro Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Point-of-Care Diagnostic Product Sales
TypeOne Time License
Description

BioMedomics generates revenue through the direct sale of its point-of-care diagnostic test kits, including Sickle SCAN, Sickle SCAN-EZ, Fungi SCAN, Femi SCAN, and previously the SARS-CoV-2 Antigen Test and COVID-19 IgM-IgG Antibody Rapid Test. Products are sold through distribution partners in over 40 countries. As a commercial-stage company acquired by OraSure Technologies in November 2025, revenue is derived from product shipments to distributors and healthcare institutions.

seekingalpha.com
2Sickle Cell Disease Grant Programs
TypeProfessional Services
Description

BioMedomics operates a grants program providing Sickle SCAN test kits (100-200 tests per project) to NGOs, clinics, and hospitals in Sub-Saharan Africa for advancing sickle cell disease testing and awareness. This program supports market development, customer acquisition, and health outcomes in under-resourced regions, indirectly contributing to long-term revenue growth through market penetration.

biomedomics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales
Pricing details1 tier
1Quote-based pricing for Sickle SCAN and other diagnostic products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

No publicly listed pricing is available. BioMedomics directs all pricing inquiries to its Request Quote form on the website and to direct sales email (sales@biomedomics.com). Pricing likely varies by product configuration (cassette vs. strip), volume, geography, and distribution arrangement.

biomedomics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Sickle SCAN
Description

Multiplexed, qualitative, point-of-care immunoassay for rapid diagnosis of sickle cell disorders. Detects hemoglobins A, S, and C to distinguish between normal, carrier, and sickle cell disease samples. Results in 5 minutes with >99% sensitivity and specificity.

biomedomics.com
+3 more records
Core offering1 text field

BioMedomics develops, manufactures, and sells rapid point-of-care diagnostic test kits and staining reagents built on proprietary lateral flow immunoassay and fluorescence-based detection technologies. Its commercial portfolio includes Sickle SCAN and Sickle SCAN-EZ for sickle cell disease screening, Fungi SCAN for fungal infection staining, and Femi SCAN for vaginal infection diagnosis, distributed globally through a network of authorized partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Sickle SCAN achieves >99% sensitivity and specificity vs. hemoglobin electrophoresis, validated in multiple peer-reviewed clinical studies including the DREPATEST study in West Africa and Kanter et al. (2015) in BMC Medicine.
+3 more records
Product overview1 text field

BioMedomics is a point-of-care diagnostic company offering a portfolio of rapid tests and staining reagents. The core products include Sickle SCAN and Sickle SCAN EZ (lateral flow immunoassays for sickle cell disease diagnosis), Fungi SCAN (all-in-one fungal staining reagent), Femi SCAN (dual fluorescence staining agent for vaginal infections), and COVID-19 tests (SARS-CoV-2 Antigen Test Kit and COVID-19 IgM-IgG Antibody Rapid Test). All products are designed for point-of-care use without need for specialized equipment, delivering laboratory-quality results in minutes. The company was acquired by OraSure Technologies in November 2025.

Product and service6 records
1Sickle SCAN
CategoryIn-Vitro Diagnostics / Hematology
Description

Multiplexed, qualitative point-of-care immunoassay that detects hemoglobins A, S, and C from a 5 µL whole-blood sample (fingerstick, heelstick, or venipuncture) to distinguish normal, carrier, and sickle cell disease samples, delivering >99% sensitivity/specificity results in 5 minutes for hospitals, clinics, blood banks, and public health programs.

2Sickle SCAN-EZ
CategoryIn-Vitro Diagnostics / Hematology
Description

Strip-format variant of the Sickle SCAN multiplexed hemoglobin A/S/C immunoassay designed for high-volume bulk screening using 2 µL of blood, delivering >99% sensitivity/specificity results in 5 minutes at a lower price point than the cassette format for public health initiatives, community screening events, and laboratories.

3Fungi SCAN
CategoryIn-Vitro Diagnostics / Microbiology
Description

All-in-one fungal staining reagent that combines potassium hydroxide (KOH) with a fluorescent compound binding to β-polysaccharides in fungal cell walls plus a counterstain, enabling rapid detection of fungal infections in skin, nail, or hair samples in under 5 minutes using fluorescence microscopy, for dermatologists, infectious disease specialists, and clinical microbiology laboratories.

4Femi SCAN
CategoryIn-Vitro Diagnostics / Women's Health
Description

Dual fluorescence staining agent using Sybr Green I and PerCP dyes to stain DNA/RNA of cells and microorganisms in vaginal secretion samples, displaying different colors under fluorescent microscopes to differentiate bacterial, fungal, and parasitic vaginal infections in approximately 2 minutes, with an optional automated slide staining system, for OB/GYN clinics and women's health laboratories.

5SARS-CoV-2 Antigen Test Kit (LFIA)
CategoryIn-Vitro Diagnostics / Infectious Disease
Description

CE approved lateral flow immunoassay detecting SARS-CoV-2 nucleocapsid protein antigen via double-antibody sandwich assay, delivering results in 15-20 minutes for healthcare providers and public health screening, approved by Saudi FDA.

6COVID-19 IgM-IgG Antibody Rapid Test
CategoryIn-Vitro Diagnostics / Infectious Disease
Description

CE approved rapid point-of-care test detecting early (IgM) and late (IgG) COVID-19 antibodies, delivering results in 10 minutes from finger-prick capillary blood, venous whole blood, serum, or plasma samples for healthcare providers and public health programs; Saudi FDA approved.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

OraSure Technologies acquired BioMedomics in November 2025 for approximately $4 million. The acquisition was designed to expand OraSure's sickle cell disease testing portfolio with particular focus on high-prevalence markets in Africa and Latin America. As a wholly-owned subsidiary of OraSure, BioMedomics benefits from OraSure's decades-long expertise in scaling life-saving diagnostics worldwide, including its global distribution channels, regulatory expertise (OraSure has two FDA submissions under review), and manufacturing capabilities. The acquisition was described as amplifying BioMedomics' mission by combining breakthrough sickle cell solutions with OraSure's proven track record in infectious disease testing.

2Sub-Saharan African NGOs, Clinics, and Hospitals (via Grant Program)
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-06-12
Description

BioMedomics launched a 3-year Independent Research Grant program starting June 19, 2024 (World Sickle Cell Day) providing Sickle SCAN test kits to NGOs, clinics, and hospitals in Sub-Saharan Africa. The program aims to increase SCD awareness, improve diagnosis and management, and support educational programs. Maximum grant is 100-200 tests per project over 3-6 month project durations. This initiative advances both social impact and market development objectives.

biomedomics.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-09-03
Description

BioMedomics partnered with Helena Laboratories Australia Pty Ltd to assist with distributing Sickle SCAN to customers in Australia following TGA (Therapeutic Goods Administration) regulatory approval in September 2020.

4Laborex Tanzania Limited
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-09-03
Description

BioMedomics partnered with Laborex Tanzania Limited to assist with distributing Sickle SCAN in Tanzania following approval by the Tanzania Medicines and Medical Devices Authority in September 2020.

biomedomics.com
5Assene-Laborex
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-10-02
Description

BioMedomics distribution partner in Nigeria, Assene-Laborex helped organize and sponsor free sickle cell screening events held during the MEA Rugby League Championship tournament in October 2019. Assene-Laborex continues to serve as BioMedomics' primary distribution partner for the Nigerian market.

biomedomics.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-10-02
Description

Euracare, a leading Nigerian healthcare provider, partnered with BioMedomics during the MEA Rugby Championship screening events, providing clinical experts to conduct sickle cell tests. The collaboration provided clinical expertise for community-based screening, demonstrating the product's ease of use in real-world healthcare settings.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2019-08-19
Description

Former Nigerian rugby player Ade Adebisi, who has sickle cell disease, was appointed as a brand ambassador for Sickle SCAN. Adebisi, also Vice Chairman and General Manager of the Nigeria Rugby League Association, serves as a patient advocate and public champion for sickle cell awareness and testing. His involvement generates grassroots awareness and lends credibility among affected communities.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Hemex Health develops the Gazelle POC hemoglobin electrophoresis diagnostic and the HemoTypeSC sickle cell trait/disease test — direct competitors in the rapid POC hemoglobin and sickle cell screening category that BioMedomics targets with Sickle SCAN.

TypeBroad incumbent
Description

QuidelOrtho is a large diagnostics incumbent with a broad portfolio of rapid immunoassay and POC tests across infectious disease, women's health, and specialty diagnostics — overlapping category presence with BioMedomics' lateral flow POC product family.

3Abbott Diagnostics
TypeBroad incumbent
Description

Abbott operates a global POC diagnostics franchise (i-STAT, Afinion, Binax) spanning immunoassays and hematology-relevant tests. It is a broad incumbent competing in POC diagnostics where BioMedomics also plays, with materially greater scale and distribution.

TypeBroad incumbent
Description

Sekisui Diagnostics is an established IVD manufacturer with rapid test platforms in infectious disease and hematology adjacent to BioMedomics' lateral flow portfolio, with broader geographic reach and larger commercial scale.

TypeDirect peer
Description

EKF Diagnostics develops POC hemoglobin and hematology analyzers (including sickle cell screening products such as the Sickle-Chex control program and point-of-care Hemo Control device), competing directly with BioMedomics in rapid hemoglobin diagnostics.

TypeBroad incumbent
Description

Bio-Rad is a diversified life science and clinical diagnostics company with a hematology diagnostics portfolio (including sickle cell testing reagents and Variant II HPLC systems) — a broad incumbent addressing the same hemoglobin disorder workflow as BioMedomics.

TypeDirect peer
Description

Trinity Biotech specializes in clinical diagnostics including hemoglobin disorder and sickle cell testing (Ultra2, HbA1c platforms), positioning it as a direct competitor in the laboratory and point-of-care hemoglobin diagnostic segment.

TypeBroad incumbent
Description

OraSure Technologies is BioMedomics' parent company following the November 2025 acquisition; it is a broader POC diagnostics incumbent with established infectious disease, substance abuse, and oral fluid testing platforms that overlap the POC lateral flow category BioMedomics serves.

TypeOthers
Description

Helena Laboratories is BioMedomics' authorized distribution partner in Australia and a broader clinical diagnostics and electrophoresis equipment supplier — an ecosystem participant rather than a direct competitor.

TypeBroad incumbent
Description

Siemens Healthineers operates a broad POC and central laboratory diagnostics portfolio (DCA Vantage, ADVIA hematology) that overlaps with BioMedomics' hemoglobin and hematology POC testing value proposition at much greater scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioMedomics

In-Vitro Diagnosticsbiomedomics.com

BioMedomics, a Morrisville, NC-based point-of-care diagnostics company, develops lateral flow immunoassay tests for sickle cell disease, fungal infections, and women's health, distributed through partners in 40+ countries. Acquired by OraSure Technologies in November 2025.

What BioMedomics does

BioMedomics is a privately-held point-of-care diagnostics company headquartered in Morrisville, North Carolina, founded in 2006-2007. The company develops lateral flow immunoassay (LFIA)-based rapid diagnostic tests for clinical and field settings without centralized laboratory infrastructure, with a primary focus on sickle cell disease (SCD) screening in resource-limited regions of Sub-Saharan Africa, the Middle East, and South Asia. Its operations are housed in a 15,000-square-foot ISO 13485-compliant research and manufacturing facility in the Research Triangle Park area.

The company's product portfolio is anchored by Sickle SCAN and Sickle SCAN-EZ — multiplexed, qualitative point-of-care immunoassays that simultaneously detect hemoglobins A, S, and C, enabling clinicians to distinguish normal, carrier, and sickle cell disease samples in 5 minutes with combined sensitivity and specificity exceeding 99% (validated against hemoglobin electrophoresis). Sickle SCAN uses a 5 µL fingerstick blood sample in cassette format, while Sickle SCAN-EZ is a 2 µL strip format designed for high-volume public-health screening at a lower per-test price. Adjacent products include Fungi SCAN (an all-in-one fluorescent KOH fungal staining reagent), Femi SCAN (a dual fluorescence staining agent for vaginal infections), and previously SARS-CoV-2 antigen and COVID-19 IgM-IgG antibody rapid tests. The company claims to be the world's leading manufacturer of hemoglobin subtype antibodies (A, C, E, F, S), supporting an intellectual property portfolio of 15 granted patents with 13 additional applications pending, backed by over $25 million in cumulative R&D investment.

BioMedomics operates a capital-light, channel-driven commercial model, selling through authorized distribution partners in more than 40 countries including Helena Laboratories (Australia), Laborex Tanzania (Tanzania), and Assene-Laborex (Nigeria). Pricing is quote-based with no publicly disclosed list rates; prospective buyers are routed through a Request Quote form and direct sales contact. The company supplements partner-channel sales with grant-funded screening initiatives — most notably a 3-year Sickle Cell Disease Independent Research Grant program in Sub-Saharan Africa launched in June 2024 — and with event-driven awareness campaigns in partnership with healthcare providers, NGOs, and patient brand ambassadors. The company is ISO 13485:2016 certified by BSI Group of America and holds regional approvals including CE mark, Saudi FDA, Australian TGA, and Tanzania TMDA. None of BioMedomics' products are currently approved for in vitro diagnostic use in the United States. In November 2025, BioMedomics was acquired by OraSure Technologies (NASDAQ: OSUR) for approximately $4 million, becoming a wholly-owned subsidiary focused on expanding sickle cell disease testing into Africa and Latin America.

BioMedomics firmographics

Firmographics
Name
BioMedomics
Legal name
BioMedomics, Inc.
Website
https://biomedomics.com
Company type
Private
Founded year
2007
Operating status
Acquired
Headcount range
11–50 employees
Short description
BioMedomics, a Morrisville, NC-based point-of-care diagnostics company, develops lateral flow immunoassay tests for sickle cell disease, fungal infections, and women's health, distributed through partners in 40+ countries. Acquired by OraSure Technologies in November 2025.
Ownership category
akta.pro rank

Where BioMedomics is headquartered

Location

Headquarters

HQ city
Morrisville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

BioMedomics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

  1. Point-of-Care Diagnostic Product Sales: BioMedomics generates revenue through the direct sale of its point-of-care diagnostic test kits, including Sickle SCAN, Sickle SCAN-EZ, Fungi SCAN, Femi SCAN, and previously the SARS-CoV-2 Antigen Test and COVID-19 IgM-IgG Antibody Rapid Test. Products are sold through distribution partners in over 40 countries. As a commercial-stage company acquired by OraSure Technologies in November 2025, revenue is derived from product shipments to distributors and healthcare institutions.
  2. Sickle Cell Disease Grant Programs: BioMedomics operates a grants program providing Sickle SCAN test kits (100-200 tests per project) to NGOs, clinics, and hospitals in Sub-Saharan Africa for advancing sickle cell disease testing and awareness. This program supports market development, customer acquisition, and health outcomes in under-resourced regions, indirectly contributing to long-term revenue growth through market penetration.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goQuote-based pricing for Sickle SCAN and other diagnostic products

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

BioMedomics product offering

Product offering

Core offering

BioMedomics develops, manufactures, and sells rapid point-of-care diagnostic test kits and staining reagents built on proprietary lateral flow immunoassay and fluorescence-based detection technologies. Its commercial portfolio includes Sickle SCAN and Sickle SCAN-EZ for sickle cell disease screening, Fungi SCAN for fungal infection staining, and Femi SCAN for vaginal infection diagnosis, distributed globally through a network of authorized partners.

Product overview

BioMedomics is a point-of-care diagnostic company offering a portfolio of rapid tests and staining reagents. The core products include Sickle SCAN and Sickle SCAN EZ (lateral flow immunoassays for sickle cell disease diagnosis), Fungi SCAN (all-in-one fungal staining reagent), Femi SCAN (dual fluorescence staining agent for vaginal infections), and COVID-19 tests (SARS-CoV-2 Antigen Test Kit and COVID-19 IgM-IgG Antibody Rapid Test). All products are designed for point-of-care use without need for specialized equipment, delivering laboratory-quality results in minutes. The company was acquired by OraSure Technologies in November 2025.

Differentiator

Problem solved

Functional benefit

Brands

  • Sickle SCAN: Multiplexed, qualitative, point-of-care immunoassay for rapid diagnosis of sickle cell disorders. Detects hemoglobins A, S, and C to distinguish between normal, carrier, and sickle cell disease samples. Results in 5 minutes with >99% sensitivity and specificity.
  • Sickle SCAN-EZ
  • Fungi SCAN
  • Femi SCAN

Products and services

  • Sickle SCAN Multiplexed, qualitative point-of-care immunoassay that detects hemoglobins A, S, and C from a 5 µL whole-blood sample (fingerstick, heelstick, or venipuncture) to distinguish normal, carrier, and sickle cell disease samples, delivering >99% sensitivity/specificity results in 5 minutes for hospitals, clinics, blood banks, and public health programs.
  • Sickle SCAN-EZ Strip-format variant of the Sickle SCAN multiplexed hemoglobin A/S/C immunoassay designed for high-volume bulk screening using 2 µL of blood, delivering >99% sensitivity/specificity results in 5 minutes at a lower price point than the cassette format for public health initiatives, community screening events, and laboratories.
  • Fungi SCAN All-in-one fungal staining reagent that combines potassium hydroxide (KOH) with a fluorescent compound binding to β-polysaccharides in fungal cell walls plus a counterstain, enabling rapid detection of fungal infections in skin, nail, or hair samples in under 5 minutes using fluorescence microscopy, for dermatologists, infectious disease specialists, and clinical microbiology laboratories.
  • Femi SCAN Dual fluorescence staining agent using Sybr Green I and PerCP dyes to stain DNA/RNA of cells and microorganisms in vaginal secretion samples, displaying different colors under fluorescent microscopes to differentiate bacterial, fungal, and parasitic vaginal infections in approximately 2 minutes, with an optional automated slide staining system, for OB/GYN clinics and women's health laboratories.
  • SARS-CoV-2 Antigen Test Kit (LFIA) CE approved lateral flow immunoassay detecting SARS-CoV-2 nucleocapsid protein antigen via double-antibody sandwich assay, delivering results in 15-20 minutes for healthcare providers and public health screening, approved by Saudi FDA.
  • COVID-19 IgM-IgG Antibody Rapid Test CE approved rapid point-of-care test detecting early (IgM) and late (IgG) COVID-19 antibodies, delivering results in 10 minutes from finger-prick capillary blood, venous whole blood, serum, or plasma samples for healthcare providers and public health programs; Saudi FDA approved.

Quantifiable outcome

  • Sickle SCAN achieves >99% sensitivity and specificity vs. hemoglobin electrophoresis, validated in multiple peer-reviewed clinical studies including the DREPATEST study in West Africa and Kanter et al. (2015) in BMC Medicine.
  • +3 more outcomes

Companies that use BioMedomics

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles4 records

BioMedomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

BioMedomics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • OraSure Technologies, Inc.coreStrategic or Co-development Partner · 1 November 2025OraSure Technologies acquired BioMedomics in November 2025 for approximately $4 million. The acquisition was designed to expand OraSure's sickle cell disease testing portfolio with particular focus on high-prevalence markets in Africa and Latin America. As a wholly-owned subsidiary of OraSure, BioMedomics benefits from OraSure's decades-long expertise in scaling life-saving diagnostics worldwide, including its global distribution channels, regulatory expertise (OraSure has two FDA submissions under review), and manufacturing capabilities. The acquisition was described as amplifying BioMedomics' mission by combining breakthrough sickle cell solutions with OraSure's proven track record in infectious disease testing.
  • Sub-Saharan African NGOs, Clinics, and Hospitals (via Grant Program)minorGTM or Marketing Partner · 12 June 2024BioMedomics launched a 3-year Independent Research Grant program starting June 19, 2024 (World Sickle Cell Day) providing Sickle SCAN test kits to NGOs, clinics, and hospitals in Sub-Saharan Africa. The program aims to increase SCD awareness, improve diagnosis and management, and support educational programs. Maximum grant is 100-200 tests per project over 3-6 month project durations. This initiative advances both social impact and market development objectives.
  • Helena Laboratories Australia Pty LtdcoreChannel Partner/ Reseller/ Distributor · 3 September 2020BioMedomics partnered with Helena Laboratories Australia Pty Ltd to assist with distributing Sickle SCAN to customers in Australia following TGA (Therapeutic Goods Administration) regulatory approval in September 2020.
  • Laborex Tanzania LimitedcoreChannel Partner/ Reseller/ Distributor · 3 September 2020BioMedomics partnered with Laborex Tanzania Limited to assist with distributing Sickle SCAN in Tanzania following approval by the Tanzania Medicines and Medical Devices Authority in September 2020.
  • Assene-LaborexcoreChannel Partner/ Reseller/ Distributor · 2 October 2019BioMedomics distribution partner in Nigeria, Assene-Laborex helped organize and sponsor free sickle cell screening events held during the MEA Rugby League Championship tournament in October 2019. Assene-Laborex continues to serve as BioMedomics' primary distribution partner for the Nigerian market.
  • EuracareminorStrategic or Co-development Partner · 2 October 2019Euracare, a leading Nigerian healthcare provider, partnered with BioMedomics during the MEA Rugby Championship screening events, providing clinical experts to conduct sickle cell tests. The collaboration provided clinical expertise for community-based screening, demonstrating the product's ease of use in real-world healthcare settings.
  • Nigeria Rugby League Association (NRLA) / Ade AdebisiminorGTM or Marketing Partner · 19 August 2019Former Nigerian rugby player Ade Adebisi, who has sickle cell disease, was appointed as a brand ambassador for Sickle SCAN. Adebisi, also Vice Chairman and General Manager of the Nigeria Rugby League Association, serves as a patient advocate and public champion for sickle cell awareness and testing. His involvement generates grassroots awareness and lends credibility among affected communities.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

BioMedomics competitors and assessment

Company assessment

Direct peers

  • Hemex Health: Hemex Health develops the Gazelle POC hemoglobin electrophoresis diagnostic and the HemoTypeSC sickle cell trait/disease test — direct competitors in the rapid POC hemoglobin and sickle cell screening category that BioMedomics targets with Sickle SCAN.
  • EKF Diagnostics: EKF Diagnostics develops POC hemoglobin and hematology analyzers (including sickle cell screening products such as the Sickle-Chex control program and point-of-care Hemo Control device), competing directly with BioMedomics in rapid hemoglobin diagnostics.
  • Trinity Biotech: Trinity Biotech specializes in clinical diagnostics including hemoglobin disorder and sickle cell testing (Ultra2, HbA1c platforms), positioning it as a direct competitor in the laboratory and point-of-care hemoglobin diagnostic segment.

Broad incumbents

  • QuidelOrtho: QuidelOrtho is a large diagnostics incumbent with a broad portfolio of rapid immunoassay and POC tests across infectious disease, women's health, and specialty diagnostics — overlapping category presence with BioMedomics' lateral flow POC product family.
  • Abbott Diagnostics: Abbott operates a global POC diagnostics franchise (i-STAT, Afinion, Binax) spanning immunoassays and hematology-relevant tests. It is a broad incumbent competing in POC diagnostics where BioMedomics also plays, with materially greater scale and distribution.
  • Sekisui Diagnostics: Sekisui Diagnostics is an established IVD manufacturer with rapid test platforms in infectious disease and hematology adjacent to BioMedomics' lateral flow portfolio, with broader geographic reach and larger commercial scale.
  • Bio-Rad Laboratories: Bio-Rad is a diversified life science and clinical diagnostics company with a hematology diagnostics portfolio (including sickle cell testing reagents and Variant II HPLC systems) — a broad incumbent addressing the same hemoglobin disorder workflow as BioMedomics.
  • OraSure Technologies: OraSure Technologies is BioMedomics' parent company following the November 2025 acquisition; it is a broader POC diagnostics incumbent with established infectious disease, substance abuse, and oral fluid testing platforms that overlap the POC lateral flow category BioMedomics serves.
  • Siemens Healthineers: Siemens Healthineers operates a broad POC and central laboratory diagnostics portfolio (DCA Vantage, ADVIA hematology) that overlaps with BioMedomics' hemoglobin and hematology POC testing value proposition at much greater scale.

Others

  • Helena Laboratories: Helena Laboratories is BioMedomics' authorized distribution partner in Australia and a broader clinical diagnostics and electrophoresis equipment supplier — an ecosystem participant rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

BioMedomics social profiles

Digital presence

BioMedomics compliance and trust

Trust signal

Compliance5 records

BioMedomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioMedomics leadership team

Management profile

Number of profiles

Profiles2 records

BioMedomics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioMedomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioMedomics

What does BioMedomics do?

BioMedomics develops, manufactures, and sells rapid point-of-care diagnostic test kits and staining reagents built on proprietary lateral flow immunoassay and fluorescence-based detection technologies. Its commercial portfolio includes Sickle SCAN and Sickle SCAN-EZ for sickle cell disease screening, Fungi SCAN for fungal infection staining, and Femi SCAN for vaginal infection diagnosis, distributed globally through a network of authorized partners.

Is BioMedomics a public or private company?

BioMedomics is a private company. It is classified as corporate owned and is currently acquired.

When was BioMedomics founded?

BioMedomics was founded in 2007. It employs 11 to 50 people.

Where is BioMedomics based?

BioMedomics is headquartered in Morrisville, United States, in the North America region.

How does BioMedomics make money?

Two revenue lines are on record. Point-of-Care Diagnostic Product Sales are the primary driver. The others are sickle Cell Disease Grant Programs.

Who are BioMedomics's main competitors?

Direct peers on record are Hemex Health, EKF Diagnostics and Trinity Biotech. Broad incumbents are QuidelOrtho, Abbott Diagnostics, Sekisui Diagnostics, Bio-Rad Laboratories, OraSure Technologies and Siemens Healthineers. Helena Laboratories is listed as an others.

Does BioMedomics have an API?

No public API is recorded for BioMedomics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewOSUR: Net loss rose to $68.7M as revenue fell 38% and COVID-19 sales were nearly eliminatedOraSure Technologies, Inc. reported a net loss of $68.7 million for the year, with revenues falling 38% year-over-year to $115.0 million, mainly due to a drastic decline in COVID-19 related sales. The company's financial performance was further impacted by exiting certain business segments while also completing the acquisition of BioMedomics and announcing a $40 million stock repurchase program.BioSpaceOraSure Announces Third Quarter 2025 Financial ResultsOraSure Technologies reported Q3 2025 revenue of $27.1 million, a 32% decline from $39.9 million in Q3 2024, with net loss widening to $13.7 million from $4.5 million. Core revenues fell 25% year-over-year driven by lower HIV test revenues and reduced sample management solutions, as some customers face funding uncertainty for public health programs. The company signed a definitive agreement to acquire BioMedomics to expand its diagnostic portfolio with the SickleSCAN rapid test for sickle cell disease, while guiding Q4 2025 revenues of $25–28 million.TipranksOraSure to acquire BioMedomics, expanding diagnostic portfolioOraSure announced it signed a definitive agreement to acquire BioMedomics, expanding its diagnostic portfolio with the addition of SickleSCAN, a rapid point-of-need test for sickle cell disease. The test is currently sold outside the United States, and OraSure believes it can significantly expand the product's reach by leveraging its international sales channels and existing relationships with national health programs. Financial terms of the transaction were not disclosed.GlobeNewswireOraSure Announces Third Quarter 2025 Financial ResultsOraSure Technologies reported Q3 2025 revenues of $27.1 million, a 32% decline from $39.9 million in Q3 2024, driven by lower HIV test and sample management revenues; the company posted a GAAP operating loss of $16.1 million compared to $6.0 million in the prior year quarter. OraSure signed a definitive agreement to acquire BioMedomics to expand its diagnostic portfolio with the SickleSCAN rapid test, and provided Q4 2025 revenue guidance of $25–28 million.GlobeNewswireCOVID-19 Rapid Test Kits Global Market Report 2022The global COVID-19 rapid test kits market is projected to fall from $21.57 billion in 2021 to $6.57 billion in 2022, a -69.5% CAGR, and further to $0.01 billion by 2026. Major players include Thermo Fisher Scientific, Abbott Laboratories, and BioMedomics. Government funding and AI integration are expected to boost growth, while product recalls may hinder it.Medical Device NetworkBD and BioMedomics roll out blood test to detect Covid-19 exposureBiotech companies BD and BioMedomics have launched a blood test to detect antibodies for current or past exposure to Covid-19, which can be completed within 15 minutes. The test is significant for providing vital data on antibody development among patients, potentially aiding researchers in understanding SARS-CoV-2 infection spread. This serology test has been clinically validated in hospitals in the US and China, ready to combat Covid-19 in the US market.BDBD, BioMedomics Announce Launch of Rapid Serology Test to Detect Exposure to COVID-19BD and BioMedomics announced a point-of-care test that detects antibodies in blood to confirm current or past COVID-19 exposure in 15 minutes. The test, available in April, is distributed by Henry Schein and can be used in labs or at the point of care. BD expects to supply over one million tests.PR NewswireBD, BioMedomics Announce Launch of Rapid Serology Test to Detect Exposure to COVID-19BD and BioMedomics announced the launch of a rapid serology test capable of detecting antibodies for current or past COVID-19 exposure in 15 minutes. The test, developed by BioMedomics and distributed exclusively by Henry Schein in the United States, is expected to begin shipping in April with an initial capacity of over one million units.GuardianAssene-Laborex offers free genotype screening, introduces BioMedomics Sickle ScanAssene-Laborex has introduced a free genotype screening service alongside the launch of the BioMedomics Sickle Scan. This initiative aims to enhance healthcare access and awareness relating to sickle cell disease. The company is actively participating in improving health outcomes in the community.